Neuphoria Therapeutics
(NASDAQ) NEUP
Neuphoria Therapeutics Financials at a Glance
Market Cap
$19.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
-$10.47M
Net Income (TTM)
-$28.48M
EPS (TTM)
$0.00
P/E Ratio
-0.15
Dividend
$0.00
Beta (Volatility)
0.65 (Low)
Dividend
$0.00
Beta (Volatility)
0.65 (Low)
Price
$3.56
Volume
9,535
Open
$3.47
Price
$3.56
Volume
9,535
Open
$3.47
Previous Close
$3.54
Daily Range
$3.47 - $3.58
52-Week Range
$3.19 - $21.40
Estimated Earnings Date
Sep 2, 2026
Dividend
$0.00
Beta (Volatility)
0.65 (Low)
Price
$3.56
Volume
9,535
Open
$3.47
Previous Close
$3.54
Daily Range
$3.47 - $3.58
52-Week Range
$3.19 - $21.40
Estimated Earnings Date
Sep 2, 2026
NEUP News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Neuphoria Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
8
CEO
Spyridon Papapetropoulos, MD, PhD
Website
www.neuphoriatx.comHeadquarters
Burlington, MA, US
NEUP Financials
Key Financial Metrics (TTM)
Gross Margin
104.75%
Operating Margin
230.73%
Net Income Margin
271.97%
Return on Equity
-113.35%
Return on Capital
-3.88%
Return on Assets
-81.82%
Earnings Yield
-6.67%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$19.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
5.40M
Volume
9.54K
Avg. Volume
64.65K
Financials (TTM)
Gross Profit
-$10.97M
Operating Income
-$24.16M
EBITDA
-$22.73M
Operating Cash Flow
$59.46M
Capital Expenditure
-$3.00
Free Cash Flow
$59.46M
Cash & ST Invst.
$19.44M
Total Debt
$34.23K
Neuphoria Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
-$165.70K
-101.1%
Gross Margin
0.00%
N/A
Market Cap
$19.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$2.39M
N/A
Employees
8
N/A
Net Income
-$505.06K
-104.5%
EBITDA
-$1.00M
-108.3%
Quarterly Fundamentals
Total Cash
$19.44M
+14.1%
Total Debt
$34.23K
-80.2%
Accounts Receivable
$1.61M
+6427.9%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$34.23K
-77.7%
Return on Assets
-81.82%
N/A
Return on Invested Capital
-72.57%
N/A
Free Cash Flow
-$3.87M
-133.8%
Operating Cash Flow
-$3.87M
-133.8%